|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2011-1-23 03:53 编辑
Not very encouraging news. Let's hope the Chinese therapeutic vaccines can make a break through. We may have to wait a bit longer, but science is making progress everyday.
并不是十分令人鼓舞的消息。希望中国治疗性疫苗可以使一个突破。我们可能不得不等待更长的时间。科学每天都在进步。[stephenw]
J Hepatol. 2011 Jan 13. [Epub ahead of print]
Therapeutic vaccines and immune-based therapies for the treatment of chronic
hepatitis B: perspectives and challenges.
Miche ML, Deng Q, Mancini-Bourgine M. Institut Pasteur, Laboratoire de Pathogenèse des virus de l'hépatite B, département de virologie ;75015 Paris, France; INSERM U845, Centre de recherche
« Croissance et signalisation », Faculté de Médecine Paris Descartes;75015
Paris, France; AP-HP, Paris, France.
Abstract
The treatment of chronic hepatitis B virus (HBV) infection has greatly improved over the last 10 years, but alternative treatments are still needed. Therapeutic vaccination is a promising new strategy for controlling chronic infection. However, this approach has not been as successful as initially anticipated for chronic hepatitis B. General impairment of the immune responses generated during persistent HBV infection, with exhausted T cells not responding correctly to therapeutic vaccination, is
probably responsible for the poor clinical responses observed to date. Intensive research efforts are now focusing on increasing the efficacy of therapeutic vaccination without causing liver disease. We describe here new approaches, for use with therapeutic vaccination, to overcome the inhibitory mechanisms impairing immune responses. We also describe innovative strategies for generating functional immune responses and inducing sustained control of this persistent infection.
Copyright © 2011. Published by Elsevier B.V.
PMID: 21238516 [PubMed - as supplied by publisher]
Ĵ肝脏病杂志。 2011年1月13日。 [EPUB的提前打印]
治疗性疫苗和治疗慢性乙型肝炎的免疫疗法乙型肝炎：展望与挑战。
Miche毫升，邓起，曼奇尼，Bourgine米
巴斯德研究所Laboratoire德Pathogenèse德德欧莱雅hépatite病毒，乙型，
省的德virologie; 75015巴黎，法国INSERM的U845，中心德recherche
« Croissance等signalisation »，Faculté德Médecine巴黎笛卡尔; 75015
巴黎，法国;美联社马力，巴黎，法国。
摘要
治疗慢性肝炎乙型肝炎病毒（HBV）感染，大大改善了过去10年，但
替代疗法仍然是必要的。治疗性疫苗是一种很有前途新的战略控制慢性感染。但是，这种方法并没有
最初被作为成功的慢性乙型肝炎一般预期减值在持续HBV感染产生的免疫反应，T细胞枯竭不正确响应治疗性疫苗，是可能对穷人负责观察到临床反应的日期。集约化目前研究工作集中在提高治疗效果
疫苗不会引起肝病。我们在这里描述的新方法，为治疗性疫苗，来克服的抑制机制损害免疫反应。我们还描述了创新战略功能产生免疫反应，并诱导该持续控制持续感染。
版权所有© 2011年。由Elsevier出版B.V.
结论：21238516 [PubMed的 - 由出版商提供] |
|
发表于 2011-1-23 03:48
